Literature DB >> 10667533

Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension.

J A Gold1, S Cullinane, J Chen, M C Oz, J A Oliver, D W Landry.   

Abstract

OBJECTIVE: To determine whether vasopressin could be effective in treating the hypotension associated with phosphodiesterase III inhibition. Phosphodiesterase III inhibitors are cardiotonic agents that increase myocardial contractility and decrease vascular smooth muscle tone. The vasodilatory effect can be profound, and the resulting hypotension frequently requires the administration of catecholamine pressors.
DESIGN: Retrospective analysis of existing data.
SETTING: The medical or surgical intensive care unit of Columbia-Presbyterian Medical Center. PATIENTS: Three consecutive patients receiving milrinone and requiring catecholamine pressors to maintain systolic arterial pressure of > or =90 mm Hg.
INTERVENTIONS: Vasopressin was administered to the three patients.
MEASUREMENTS AND MAIN RESULTS: Vasopressin (0.03-0.07 units/min) increased systolic arterial pressure from 90+/-4.7 to 130+/-2.3 mm Hg while reducing the administration of catecholamine pressors.
CONCLUSIONS: Vasopressin at very low doses appears to be an effective vasopressor for milrinone-induced hypotension.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10667533     DOI: 10.1097/00003246-200001000-00043

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  10 in total

1.  Vasoplegic syndrome after off-pump coronary artery bypass surgery: an unusual complication.

Authors:  Shahzad G Raja; Gilles D Dreyfus
Journal:  Tex Heart Inst J       Date:  2004

Review 2.  Management of vasodilatory shock: defining the role of arginine vasopressin.

Authors:  Martin W Dunser; Volker Wenzel; Andreas J Mayr; Walter R Hasibeder
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Use of vasopressin in neonatal hypertrophic obstructive cardiomyopathy: case series.

Authors:  Stephanie M Boyd; Kristin L Riley; Regan E Giesinger; Patrick J McNamara
Journal:  J Perinatol       Date:  2020-09-19       Impact factor: 2.521

Review 4.  Role of vasopressin in the management of septic shock.

Authors:  Gökhan M Mutlu; Phillip Factor
Journal:  Intensive Care Med       Date:  2004-04-21       Impact factor: 17.440

5.  [Vasopressin as a rescue vasopressor agent. Treatment of selected cardiogenic shock states].

Authors:  V D Mayr; G Luckner; S Jochberger; V Wenzel; W R Hasibeder; M W Dünser
Journal:  Anaesthesist       Date:  2007-10       Impact factor: 1.041

6.  Norepinephrine for hypotensive vasodilatation after cardiac surgery: impact on renal function.

Authors:  Hiroshi Morimatsu; Shigehiko Uchino; John Chung; Rinaldo Bellomo; Jai Raman; Brian Buxton
Journal:  Intensive Care Med       Date:  2003-05-22       Impact factor: 17.440

Review 7.  Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa.

Authors:  Todd W Rice
Journal:  Vasc Health Risk Manag       Date:  2006

Review 8.  Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology.

Authors:  Cheryl L Holmes; Donald W Landry; John T Granton
Journal:  Crit Care       Date:  2003-06-26       Impact factor: 9.097

9.  Terlipressin versus norepinephrine to prevent milrinone-induced systemic vascular hypotension in cardiac surgery patient with pulmonary hypertension.

Authors:  Mai Mohsen Abdelazziz; Hadil Magdi Abdelhamid
Journal:  Ann Card Anaesth       Date:  2019 Apr-Jun

10.  Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in mice.

Authors:  Toonchai Indrambarya; John H Boyd; Yingjin Wang; Melissa McConechy; Keith R Walley
Journal:  Crit Care       Date:  2009-06-23       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.